GoAI
Get started
Rapid Micro Biosystems, Inc. logo

Rapid Micro Biosystems, Inc.

RPID

NASDAQHealthcareMedical - Devices

Open in GoAI

Previous close

$1.68

+$0.01 · +0.60%

Aug 21, 4:00 PM ET

RPID company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

60

Fair Value

Momentum

37

Weakening

Sentiment

65

Bullish

Risk resilience

24

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Rapid Micro Biosystems, Inc. operates as a life sciences technology firm, supplying advanced solutions for identifying microbial impurities in the production processes of pharmaceuticals, medical devices, and personal care goods across North America, Europe, and Asia. Central to their offerings is the Growth Direct platform, a comprehensive system comprising the Growth Direct instrument, specialized disposable components, software for seamless integration with laboratory information management systems (LIMS), and extensive customer validation and support services. This innovative platform is designed to automate and modernize traditional, labor-intensive microbial quality control (MQC) testing workflows, which are critical for diverse therapeutic modalities such as biologics, vaccines, cutting-edge cell and gene therapies, and sterile injectable medications. Beyond their core product, the company also delivers essential services, including system installation, verification, expert technical training, and continuous support. Their technologies are widely applied in vital areas like environmental monitoring, water quality testing, bioburden assessment, and final sterility release evaluations. Established in 2006, the company initially traded as Genomic Profiling Systems, Inc., before rebranding to Rapid Micro Biosystems, Inc. in January 2007, and maintains its headquarters in Lowell, Massachusetts.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Robert G. Spignesi Jr.
Listed since
Jul 15, 2021
Employees
171

Market position

Day range

Current $1.68

52-week range

Current $1.68

Open
$1.69
Previous close
$1.67
Volume
122.66K
0.62× average
Average volume
198.61K
Average daily volume
Market cap
76.14M USD
Beta
1.48
Market reference 1
50-day average
$1.8508
-9.23% below average
200-day average
$2.8505
-41.06% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
133.41M USD
P/E (TTM)
-1.51×
P/B (TTM)
4.45×
P/S (TTM)
2.16×
EV / EBITDA
-3.12×
Earnings yield
-36.37%
Free cash flow yield
-24.63%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
10.03%
Operating margin
-141.45%
Net margin
-145.56%
Return on equity
-141.91%
Return on assets
-62.95%
Return on invested capital
-82.19%

Financial health

Debt / equity
1.32×
Current ratio
3.31×
Altman Z-score
-13.61
Piotroski F-score
2 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends62%-95%-251%-408%Gross margin, FY2021: -33.32%Gross margin, FY2022: -49.85%Gross margin, FY2023: -24.36%Gross margin, FY2024: -0.39%Gross margin, FY2025: 22.65%Operating margin, FY2021: -203.31%Operating margin, FY2022: -368.99%Operating margin, FY2023: -251.18%Operating margin, FY2024: -177.96%Operating margin, FY2025: -141.10%Net margin, FY2021: -316.48%Net margin, FY2022: -354.91%Net margin, FY2023: -232.99%Net margin, FY2024: -167.16%Net margin, FY2025: -140.30%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 -33.32%. Gross margin FY2022 -49.85%. Gross margin FY2023 -24.36%. Gross margin FY2024 -0.39%. Gross margin FY2025 22.65%. Operating margin FY2021 -203.31%. Operating margin FY2022 -368.99%. Operating margin FY2023 -251.18%. Operating margin FY2024 -177.96%. Operating margin FY2025 -141.10%. Net margin FY2021 -316.48%. Net margin FY2022 -354.91%. Net margin FY2023 -232.99%. Net margin FY2024 -167.16%. Net margin FY2025 -140.30%.

Income trends

Revenue

33.59M USD+19.74%

Operating income

−47.39M USD+5.06%

Net income

−47.12M USD-0.50%
Income trends across reported periods44.3M USD1.45M USD−41.39M USD−84.24M USDRevenue, FY2021: 23.23M USDRevenue, FY2022: 17.13M USDRevenue, FY2023: 22.52M USDRevenue, FY2024: 28.05M USDRevenue, FY2025: 33.59M USDOperating income, FY2021: −47.23M USDOperating income, FY2022: −63.22M USDOperating income, FY2023: −56.56M USDOperating income, FY2024: −49.92M USDOperating income, FY2025: −47.39M USDNet income, FY2021: −73.52M USDNet income, FY2022: −60.81M USDNet income, FY2023: −52.47M USDNet income, FY2024: −46.89M USDNet income, FY2025: −47.12M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 23.23M USD. Revenue FY2022 17.13M USD. Revenue FY2023 22.52M USD. Revenue FY2024 28.05M USD. Revenue FY2025 33.59M USD. Operating income FY2021 −47.23M USD. Operating income FY2022 −63.22M USD. Operating income FY2023 −56.56M USD. Operating income FY2024 −49.92M USD. Operating income FY2025 −47.39M USD. Net income FY2021 −73.52M USD. Net income FY2022 −60.81M USD. Net income FY2023 −52.47M USD. Net income FY2024 −46.89M USD. Net income FY2025 −47.12M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue33.59M USD28.05M USD22.52M USD17.13M USD23.23M USD
Cost of goods sold25.98M USD28.16M USD28M USD25.67M USD30.97M USD
Gross profit7.61M USD−109K USD−5.49M USD−8.54M USD−7.74M USD
Research and development13.6M USD14.6M USD12.82M USD12.87M USD9.78M USD
Selling, general, and administrative34.84M USD35.21M USD38.26M USD41.81M USD29.71M USD
Operating expenses55M USD49.81M USD51.08M USD54.68M USD39.49M USD
Interest income1.51M USD3.16M USD4.21M USD1.78M USD—
Interest expense1.09M USD———2.65M USD
Depreciation and amortization3.25M USD3.36M USD3.11M USD2.84M USD1.53M USD
Operating income−47.39M USD−49.92M USD−56.56M USD−63.22M USD−47.23M USD
Net income−47.12M USD−46.89M USD−52.47M USD−60.81M USD−73.52M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
18%
2 beats, 6 misses, 3 met estimates
Average EPS surprise
-4.65%
11 comparable reports
Latest EPS result
-0.27
Estimate -0.24 · Miss by 10.96%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.16-0.22-0.29-0.35Q1 '25MetQ2 '25BeatQ3 '25MissQ4 '25MetQ1 '26MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 28, 2025: actual -0.22, estimate -0.22, surprise 0.00%, Met estimate. Q2 2025, reported May 9, 2025: actual -0.26, estimate -0.27, surprise +3.70%, Beat. Q3 2025, reported Aug 12, 2025: actual -0.27, estimate -0.26, surprise -3.85%, Miss. Q4 2025, reported Nov 7, 2025: actual -0.26, estimate -0.26, surprise 0.00%, Met estimate. Q1 2026, reported Mar 12, 2026: actual -0.28, estimate -0.23, surprise -21.74%, Miss. Q2 2026, reported May 13, 2026: actual -0.31, estimate -0.25, surprise -24.00%, Miss. Q3 2026, reported Aug 7, 2026: actual -0.27, estimate -0.243, surprise -10.96%, Miss. Q4 2026, reported Nov 6, 2026: actual —, estimate -0.19, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates11.8M10.01M8.21M6.41MQ1 '25BeatQ2 '25BeatQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 28, 2025: actual 8.22M USD, estimate 8.2M USD, surprise +0.22%, Beat. Q2 2025, reported May 9, 2025: actual 7.21M USD, estimate 6.87M USD, surprise +4.93%, Beat. Q3 2025, reported Aug 12, 2025: actual 7.26M USD, estimate 8.33M USD, surprise -12.86%, Miss. Q4 2025, reported Nov 7, 2025: actual 7.84M USD, estimate 10.93M USD, surprise -28.31%, Miss. Q1 2026, reported Mar 12, 2026: actual 11.28M USD, estimate 11.35M USD, surprise -0.60%, Miss. Q2 2026, reported May 13, 2026: actual 8M USD, estimate 7.6M USD, surprise +5.29%, Beat. Q3 2026, reported Aug 7, 2026: actual 8.05M USD, estimate 7.88M USD, surprise +2.27%, Beat. Q4 2026, reported Nov 6, 2026: actual —, estimate 9.98M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$7.00

316.67% upside
Past 12 months12-month forecastHigh $7.00Average $7.00Low $7.00

Rating distribution

6 ratings
Strong buy00%
Buy467%
Hold233%
Sell00%
Strong sell00%

Recent analyst actions

2 institutions
KeybancmaintainOverweight
Lake StreetmaintainBuy

RPID news

zacks.com

Down 25.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Rapid Micro Biosystems (RPID)

The heavy selling pressure might have exhausted for Rapid Micro Biosystems (RPID) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in…

Read source
defenseworld.net

Many Bright Ideas Technologies (OTCMKTS:MBGNF) versus Rapid Micro Biosystems (NASDAQ:RPID) Head to Head Contrast

Many Bright Ideas Technologies (OTCMKTS:MBGNF - Get Free Report) and Rapid Micro Biosystems (NASDAQ: RPID - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two…

Read source
zacks.com

Rapid Micro Biosystems (RPID) Upgraded to Buy: What Does It Mean for the Stock?

Rapid Micro Biosystems (RPID) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Read source
seekingalpha.com

Rapid Micro Biosystems, Inc. (RPID) Q2 2026 Earnings Call Transcript

Rapid Micro Biosystems, Inc. (RPID) Q2 2026 Earnings Call Transcript

Read source
marketbeat.com

Rapid Micro Biosystems Q2 Earnings Call Highlights

Rapid Micro Biosystems NASDAQ: RPID reported second-quarter revenue of $8.1 million, up 11% from $7.3 million a year earlier and above the company's prior guidance, as consumable sales, service activity and recurring…

Read source
zacks.com

Rapid Micro Biosystems, Inc. (RPID) Reports Q2 Loss, Tops Revenue Estimates

Rapid Micro Biosystems, Inc. (RPID) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to a loss of $0.27 per share a year ago.

Read source

RPID peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding RPID

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
1.6M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
431.88K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
189.72K
Weight
0.01%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
Dimensional - US Small Cap ETF logoDimensional - US Small Cap ETFDFAS
Market value
51.28K
Weight
0.00%
AUM
15.92B USD
Expense ratio
0.26%
Price / 1D
$83.02+0.73%
U.S. Micro Cap Portfolio ETF logoU.S. Micro Cap Portfolio ETFDFMC
Market value
23.99K
Weight
0.00%
AUM
8.06B USD
Expense ratio
0.43%
Price / 1D
$60.95+0.73%
Avantis U.S. Small Cap Equity ETF logoAvantis U.S. Small Cap Equity ETFAVSC
Market value
19.44K
Weight
—
AUM
3.16B USD
Expense ratio
0.25%
Price / 1D
$73.84+0.70%

Continue in GoAI

Research RPID

research.disclaimer